After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

Manhattan-based dentist Dr. Sandip Sachar and obesity medicine specialist Dr. Meghan Garcia-Webb discuss the prevalence of ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more research is needed.

Ozempic, while effective for weight loss, is linked to emerging dental problems termed \"Ozempic teeth.\" Patients report dry ...

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and honor the scientists behind the discovery of the role of GLP-1. Following the ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

Weight loss jabs could reduce the risk of up to 14 types of cancer, new research has found. Mounjaro, Ozempic and other ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.